Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) (NCT04603495)

🧪 Interventions in This Study

• Pelabresib (DRUG)
• Ruxolitinib (DRUG)
• Placebo (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (156 Sites)

Showing the first 25 of 156 sites.

• University of Alabama at Birmingham — Birmingham, Alabama
• Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers — Chandler, Arizona
• UC San Diego Moores Cancer Center — La Jolla, California
• USC/Norris Comprehensive Cancer Center — Los Angeles, California
• UCLA Medical Center — Los Angeles, California
• Yale University School of Medicine — New Haven, Connecticut
• Mayo Clinic — Jacksonville, Florida
• Moffitt Cancer Center — Tampa, Florida
• Decatur Memorial Hospital Cancer Care Center of Decatur/Cancer Care Specialists of IL — Decatur, Illinois
• Franciscan Health/Indiana blood and Marrow Transplantation — Indianapolis, Indiana
• Norton Cancer Institute, St. Matthews Campus — Louisville, Kentucky
• University of Michigan Medical Center — Ann Arbor, Michigan
• Washington University — St Louis, Missouri
• Icahn School of Medicine at Mount Sinai — New York, New York
• Memorial Sloan Kettering Cancer Center — New York, New York
• Weill Cornell Medical College- New York Presbyterian Hospital — New York, New York
• Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio
• MD Anderson Cancer Center — Houston, Texas
• University of Texas Health Science Center - San Antonio — San Antonio, Texas
• Center for Blood Disorders and Cellular Therapy, Swedish Cancer Institute — Seattle, Washington
• Icon Cancer Centre — Brisbane, Queensland
• Royal Adelaide Hospital — Adelaide, South Australia
• Monash Health — Clayton, Victoria
• Peninsula Private Hospital Clinical Trials Unit — Frankston, Victoria
• USC Clinical Trials Centre Sunshine Coast Haematology and Oncology Clinic — Buderim,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Myelofibrosis

• Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms — Birmingham, Alabama
• Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis — Calgary, Alberta
• Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis — Birmingham, Alabama
• A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis — Pasadena, California
• A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) — Newport Beach, California

Explore by condition: All Myelofibrosis clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.